NSABP B-54-I
NSABP B-54-I
Phase III Study Evaluating Palbociclib (PD-0332991) and a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (PENELOPE) Global Accrual = 1250
Patient Population:
Patients with hormone receptor-positive, HER2-normal breast cancer with residual disease following neoadjuvant chemotherapy and surgery
Target Accrual: 171 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT01864746
Phase III Study Evaluating Palbociclib (PD-0332991) and a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (PENELOPE) Global Accrual = 1250
Patient Population:
Patients with hormone receptor-positive, HER2-normal breast cancer with residual disease following neoadjuvant chemotherapy and surgery
Target Accrual: 171 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT01864746